Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02965456 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

A Phase 3 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 3
Development phase
820
Enrollment target

NCT02965456 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 820 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02965456, a Phase 3 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 3
Development phase
820 participants
Enrollment target

Study Summary

The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score \[EGSS\] of 3 \[moderate\] or 4 \[severe\]).

Interventions

  • DRUG IDP 121 Lotion
  • DRUG IDP-121 Vehicle Lotion

Trial Details

FieldValue
Enrollment Target 820 participants
Start Date 2015-11-04
Est. Completion 2017-02-23
Phase Phase 3

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT02965456

The ClinicalTrials.gov registry entry for NCT02965456 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which IDP 121 Lotion is the first listed.

NCT02965456 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02965456 about?

NCT02965456 is a clinical study titled "Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris". The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severit...

What is the current status of trial NCT02965456?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2015-11-04. Estimated completion is 2017-02-23.

What interventions are being tested in trial NCT02965456?

The interventions under investigation include: IDP 121 Lotion (DRUG), IDP-121 Vehicle Lotion (DRUG).

Who is sponsoring clinical trial NCT02965456?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.